Vizient, Inc. released its new Spend Management Outlook representing the best estimate of the change in the price of pharmaceuticals, medical devices and supplies, capital equipment and services ...

Humira®, manufactured by AbbVie ... Biosimilars continue to gain influence. A comprehensive biosimilar chart featured in the Outlook includes 24 molecules with corresponding FDA-approved ...

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar ... about the Humira erosion curve ...

A few initial considerations outlined on this chart regarding the planned ... throughout the year as the number of biosimilar entrants increase. HUMIRA's erosion curve, once faced with material ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...

Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the blockbuster marks its second anniversary of its U.S. biosimilar threat. The anti-inflammatory injection ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...